Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Stock Information for Alterity Therapeutics Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Alterity Therapeutics Limited

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System
Alterity Therapeutics: Appendix 4C - Q1 FY26 Quarterly Cash Flow Report
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders
Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
Alterity Therapeutics Raises A$20.0 million in Strategic Placement
Alterity Therapeutics to Present at the Biotech Showcase

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.